CRSP|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $-1.05 | - | - |
| Q3'25 | $-1.29 | $-1.17 | +9.2% |
| Q2'25 | $-1.40 | $-1.29 | +7.8% |
| Q1'25 | $-1.28 | $-1.58 | -23.8% |
| Q4'24 | $-1.19 | $-0.44 | +62.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $10M | - | - |
| Q3'25 | - | $889,000 | - |
| Q2'25 | - | $892,000 | - |
| Q1'25 | - | $865,000 | - |
| Q4'24 | - | $36M | - |
CRSP|Monthly Returns
Market Data
CRSP Stock Snapshot
- Market cap
- 5.12B
- Day range
- $51.70 – $53.60
- News sentiment
- 55/100 · Neutral
- Analyst target
- $87.56 (+68.4%)
- Consensus
- Buy · 30 analysts
Neither side has the upper hand on CRSP right now, and the indicator set reflects that. Company-specific news dominates here; sector-level flows matter less than for larger names.
Behaviour On Record
What CRSP's own history says about today's numbers
- Realized volatility (21d)
- 56.7% 44th pct
- Below its peak
- -75.3%
- vs 200-day average
- -1.3%
- Up days (1y)
- 46%
CRISPR Therapeutics AG is currently running 56.7% annualised volatility over the last 21 sessions. Measured against CRSP's own 10 years of daily returns rather than a market-wide average, that is the 44th percentile — close to its own typical level, against a typical reading of 59.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
CRSP is trading -75.3% below its running peak. Across 9 full years on file, its median worst-drawdown-in-a-year was -43.6%, and the deepest was -67.2% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -1.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 48th percentile — close to the gap it normally carries. Over the past year CRSP closed higher on 46% of sessions, and it is currently 1 session into a rising streak.
On September specifically: over 9 years of records, CRSP finished the month higher 2 of 9 times, with a median return of -9.7% and an average of -5.3%. Its strongest month historically has been November at +15.1% on average, its weakest March at -9.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: CRSP has opened more than 2% away from the prior close in 361 of 2,487 sessions (14.5% of the time), with the largest gaps running +13.9% and -10.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 2,488 daily closes between 2016-10-19 and 2026-09-14, split-adjusted, recomputed daily. Percentiles are against CRSP's own 10-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CRSP's sector?
CRISPR Therapeutics AG sits in the Health Care sector, currently ranked 3rd of 11 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, CRSP ranks 4th of 15 tracked industries, lagging.
- Sector rank
- #3 of 11
- Sector state
- Leading
- Sector rotation score
- 80
- Industry rank
- #4 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on CRSP?
Citizens most recently reiterated its rating on CRISPR Therapeutics AG to Market Outperform on Aug 31, 2026 with a price target of $80. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Citizens — Market Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
